Sign in

CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company

Ernexa Therapeutics Inc.

Sign in to watch
Ticker
ERNA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
311103425
Phone
(617) 798-6700
Business address
1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
Former names
Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC

Securities

  • ERNA Common Stock Nasdaq
  • ERNAW Warrants Nasdaq
  1. 4 Open-market buy Director bought 4,000 shares at an average $5.37 ($21,480)
  2. 10-Q Report Quarterly Report
  3. 8-K Event Results of operations
  4. 4 Open-market buy SVP Marketing bought 2,000 shares at an average $4.75 ($9,508)
  5. 4 Open-market buy CEO bought 3,000 shares at an average $4.85 ($14,562)
  6. 8-K Event Bylaws or fiscal year change · Other events
  7. 4 Open-market buy SVP Marketing bought 40,000 shares at an average $0.12 ($4,664)
  8. 4 Open-market buy CFO and EVP bought 15,000 shares at $0.12 ($1,793)
  9. 4 Open-market buy SVP Marketing bought 30,000 shares at $0.12 ($3,600)
  10. 8-K Event Shareholder vote results · Other events
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Open-market buy SVP Marketing bought 20,000 shares at $0.16 ($3,200)
  16. 4 Open-market buy Director bought 65,000 shares at an average $0.17 ($10,898)
  17. 4 Derivatives Options or other derivatives
  18. 4 Open-market buy CEO bought 50,000 shares at an average $0.16 ($7,998)
  19. 4 Open-market buy SVP Marketing bought 50,000 shares at an average $0.17 ($8,433)
  20. 3 Insider Initial Statement of Ownership

Page 38 of 77 · 1,525 filings